Celgene results beat forecasts, as Revlimid delivers
Oct 25 (Reuters) - Celgene Corp's quarterly results beat expectations on strong sales of its Revlimid cancer treatment, and the biotechnology company narrowly raised its full-year profit forecast.
The company on Thursday said it earned $424 million, or 97 cents per share in the third quarter. That compared with $373 million, or 81 cents per share, in the year-earlier period.
Excluding special items, Celgene earned $1.29 per share. Analysts, on average, had expected $1.27 per share, according to Thomson Reuters I/B/E/S.
Global company revenue rose 14 percent to $1.42 billon, topping Wall Street expectations of $1.41 billion.
(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)